Induction of experimental Candida arthritis in rats.

J Med Vet Mycol

Department of Dental Pharmacology, Nippon Dental University, Niigata, Japan.

Published: October 1991

AI Article Synopsis

Article Abstract

Experimental arthritis, caused by intravenously (IV) introduced Candida albicans, has been induced for the first time in rats. Four-week-old Sprague-Dawley rats were inoculated IV with three different strains of C. albicans and observed for 4 weeks. Each of the three strains tested was able to produce arthritis. The incidence of Candida arthritis increased in a dose-dependent manner and was more than 90% at sublethal doses. Joints of the limbs were affected predominantly, and at higher doses arthritis was produced in multiple (four or five) joints in individual animals, showing it to be polyarthritis. C. albicans was recovered from all cultures of affected limb joints, which were excised 12, 19 and 28 days after inoculation and showed different stages and degrees of joint swelling. Results of histopathology and radiography showed that the Candida arthritis involved not only periarticular inflammation but also changes in joint bones. In particular, metaphyseal enlargement, punched-out lesions at the diaphysis and the appearance of osteoclasts were the most prominent changes in affected bones. These pathological features are compared with those of Candida arthritis in humans.

Download full-text PDF

Source

Publication Analysis

Top Keywords

candida arthritis
16
three strains
8
arthritis
7
candida
5
induction experimental
4
experimental candida
4
arthritis rats
4
rats experimental
4
experimental arthritis
4
arthritis caused
4

Similar Publications

Objectives: Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL-17A, previously demonstrated efficacy and was well tolerated to 1 year in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA). Here, we report bimekizumab safety and efficacy to 2 years.

Methods: Patients completing week 52 in the phase 3 studies BE MOBILE 1 (nr-axSpA; NCT03928704) and 2 (r‑axSpA; NCT03928743) were eligible for an ongoing open‑label extension (OLE; NCT04436640).

View Article and Find Full Text PDF

[Septic musculoskeletal complications under immunomodulating treatment].

Z Rheumatol

January 2025

Rheumatologische Facharztpraxis Schwerin, Schwerin, Deutschland.

Infections are an important cause of morbidity and mortality in patients with inflammatory rheumatic diseases. Among these, musculoskeletal infections represent a relevant proportion as patients with rheumatoid arthritis face an increased risk of developing septic arthritis and prosthesis infections. The causes are multifactorial.

View Article and Find Full Text PDF

Evidence suggests that the gut microbiome may play a role in multiple sclerosis (MS). However, the majority of the studies have focused on gut bacterial communities; none have examined the fungal microbiota (mycobiota) in persons with pediatric-onset multiple sclerosis (POMS). We examined the gut mycobiota in persons with and without POMS through a cross-sectional examination of the gut mycobiota from 46 participants' stool samples (three groups: 18 POMS, 13 acquired monophasic demyelinating syndromes [monoADS], and 15 unaffected controls).

View Article and Find Full Text PDF

The majority of pediatric fungal septic arthritis patients are infants. Risk factors include prematurity and neonatal septicemia with prolonged hospitalization. Here, we present a case of a two-month-old male infant, preterm at 28 weeks and NICU graduate.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!